Anesthesia for Renal Transplantation

Renal transplantation is the preferred mode of replace ment therapy for most patients with end-stage renal disease (ESRD) and accounts for nearly 60% of all organ transplants in the United States. While as many as 35,000 people remain on the list waiting to receive a cadaveric kidney, living-related renal transplantation offers a shorter waiting period and greater survival. Maximization of the health of the kidney recipient before transplantation can improve ultimate outcome. Proper anesthetic management is facilitated by under standing the physiology and pharmacology of ESRD. Maintaining intraoperative blood volume is a key to good graft function, especially the living-related pediat ric kidney recipient. Recent improvements in combined immnosuppression therapy have improved the overall outcome in transplant recipients. The average 3-year survival is nearly 75%.

[1]  P. Padfield,et al.  Renal , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[2]  S. Flechner.  Current status of renal transplantation. Patient selection, results, and immunosuppression. , 1994, The Urologic clinics of North America.

[3]  L. Margolius,et al.  The Effect of Dopamine on Graft Function in Patients Undergoing Renal Transplantation , 1993, Anesthesia and analgesia.

[4]  P. Kurnik,et al.  Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. , 1993, Renal failure.

[5]  R. Miller,et al.  Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. , 1992, Anesthesiology.

[6]  A. Bersten,et al.  Dopamine and Renal Salvage in the Critically Ill Patient , 1992, Anaesthesia and intensive care.

[7]  D. Dunn,et al.  Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. , 1992, Transplantation.

[8]  A. Sagalowsky,et al.  Intraoperative albumin administration affects the outcome of cadaver renal transplantation. , 1992, Transplantation.

[9]  J. Lerman,et al.  Haemodynamic and organ blood flow responses to sevoflurane during spontaneous ventilation in the rat: a dose-response study , 1992 .

[10]  H. Sollinger,et al.  RS‐61443—A PHASE I CLINICAL TRIAL AND PILOT RESCUE STUDY 1 , 1992, Transplantation.

[11]  B. Jaffee,et al.  THE EFFECT OF A NEW IMMUNOSUPPRESSIVE DRUG, BREQUINAR SODIUM, ON HEART, LIVER, AND KIDNEY ALLOGRAFT REJECTION IN THE RAT , 1992, Transplantation.

[12]  W K Vaughn,et al.  Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States. , 1992, JAMA.

[13]  G. Nordén,et al.  Living Donor Nephrectomy: Complication Rates in 490 Consecutive Cases , 1992 .

[14]  A. Demetris,et al.  FK 506 in clinical kidney transplantation. , 1991, Transplantation proceedings.

[15]  K. Belani,et al.  Kidney Transplantation , 1991, International anesthesiology clinics.

[16]  P. Terasaki,et al.  Outcome of renal transplantation in different primary diseases. , 1991, Clinical transplants.

[17]  A. Keogh,et al.  Renal donors--how selective should we be? , 1990, Transplantation proceedings.

[18]  P. Morris,et al.  Triple therapy immunosuppression in cadaveric renal transplantation , 1990, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  J. Salaman,et al.  Calcium-channel blockers and other factors influencing delayed function in renal allografts. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  R. Ricketts.  The renal response to low dose dopamine , 1989 .

[21]  S. Berkman,et al.  Hematologic aspects of renal insufficiency. , 1989, Blood reviews.

[22]  R. Andersen,et al.  THE IMPACT OF DIABETES ON VASCULAR COMPLICATIONS FOLLOWING CADAVER RENAL TRANSPLANTATION , 1987, Transplantation.

[23]  T. Starzl,et al.  Living donors: con. , 1987, Transplantation proceedings.

[24]  M. Henry,et al.  SEQUENTIAL ANTILYMPHOBLAST GLOBULIN AND CYCLOSPORINE FOR RENAL TRANSPLANTATION , 1987, Transplantation.

[25]  P. Rosenberg,et al.  Anaesthesiological complications in renal transplantation: a retrospective study of 500 transplantations , 1986, Acta anaesthesiologica Scandinavica.

[26]  E. Thorsby,et al.  Renal transplants from HLA-haploidentical living-related donors. The influence of donor-specific transfusions and different immunosuppressive regimens. , 1986, Transplantation.

[27]  B. Weatherley,et al.  Pharmacokinetics of atracurium and its metabolites. , 1986, British journal of anaesthesia.

[28]  C. F. Anderson,et al.  The risks of unilateral nephrectomy: status of kidney donors 10 to 20 years postoperatively. , 1985, Mayo Clinic proceedings.

[29]  R. Miller,et al.  The Pharmacokinetics and Pharmacodynamics of Atracurium in Patients with and without Renal Failure , 1984, Anesthesiology.

[30]  K. Piafsky,et al.  Clinical significance of plasma binding of basic drugs , 1981 .

[31]  D. W. Ryan.  Preoperative serum cholinesterase concentration in chronic renal failure. Clinical experience of suxamethonium in 81 patients undergoing renal transplant. , 1977, British journal of anaesthesia.

[32]  C. Bahr,et al.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. , 1971, The New England journal of medicine.

[33]  K. Dhunér,et al.  Anesthesia in renal transplantation. Observations at 142 anesthetics in 50 patients. , 1968, Scandinavian journal of urology and nephrology.

[34]  J. Cerny,et al.  Current status of renal transplantation. , 1966, Michigan medicine.